Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.,Cancer Gene Therapy

当前位置： X-MOL 学术 › Cancer Gene Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.
Cancer Gene Therapy ( IF 4.8 ) Pub Date : 2019-07-11 , DOI: 10.1038/s41417-019-0119-5
Longzhen Cui _{1,

2,

3,

4} , Yan Liu ₂ , Yifan Pang ₅ , Tingting Qian _{1,

4} , Liang Quan _{1,

4} , Zhiheng Cheng ₆ , Yifeng Dai ₇ , Xu Ye ₁ , Ying Pang ₁ , Jinlong Shi ₈ , Xiaoyan Ke ₉ , Depei Wu ₁₀ , Lin Fu _{1,

3,

4}

Affiliation

Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China.
Translational Medicine Center, Huaihe Hospital of Henan University, Kaifeng, 475000, China.
Department of Hematology, Huaihe Hospital of Henan University, Kaifeng, 475000, China.
Translational Medicine Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China.
Department of Medicine, William Beaumont Hospital, Royal Oak, MI, 48073, USA.
Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Immunoendocrinology, Division of Medical Biology, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Department of Biomedical Engineering, Chinese PLA General Hospital, 100853, Beijing, China.
Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, 100191, Beijing, China.
Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.

Relapsed and refractory acute myeloid leukemia (R/R AML) has complicated pathogenesis. Its treatment is complicated, and the prognosis is poor. So far, there is no consensus on what is the optimal treatment strategy. With the deepening of research, new chemotherapy regimens, new small molecule inhibitors, and immunotherapy have been increasingly applied to clinical trials, providing more possibilities for the treatment of R/R AML. The most effective treatment for patients who achieve complete remission after recurrence is still sequential conditioning therapy followed by allogeneic hematopoietic cell transplantation. Finding the best combination of treatments is still an important goal for the future.

中文翻译：

用于治疗复发性和难治性急性髓细胞性白血病的新兴药物和治疗方案。

复发和难治性急性髓细胞性白血病（R / R AML）具有复杂的发病机理。治疗复杂，预后差。迄今为止，关于什么是最佳治疗策略尚无共识。随着研究的深入，新的化学疗法，新的小分子抑制剂和免疫疗法已越来越多地应用于临床试验，为R / R AML的治疗提供了更多可能性。对于复发后完全缓解的患者，最有效的治疗仍然是序贯调理治疗，然后进行异基因造血细胞移植。寻找最佳治疗组合仍然是未来的重要目标。

更新日期：2019-11-18

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11